- The FDA approved Ferring Pharmaceuticals' new manufacturing facility in Parsippany, NJ, to produce ADSTILADRIN® (nadofaragene firadenovec-vncg).
- This expansion will ensure a sustainable supply to meet the global demand for ADSTILADRIN.
- The approval triggers a final $200 million payment from Royalty Pharma (RPRX, Financial) to Ferring Pharmaceuticals.
Ferring Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its new state-of-the-art manufacturing facility in Parsippany, New Jersey. This facility is dedicated to producing ADSTILADRIN® (nadofaragene firadenovec-vncg), an intravesical non-replicating gene therapy for high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
The new facility joins two other manufacturing sites in Kuopio, Finland, further enhancing Ferring’s capacity to meet the growing global demand for its innovative bladder cancer treatment. The Parsippany site features advanced technology and equipment designed to ensure a stable and sustainable supply of ADSTILADRIN.
ADSTILADRIN is the first and only FDA-approved intravesical non-replicating gene therapy for NMIBC. It represents a significant advancement for patients who do not respond to traditional BCG therapy, which remains the first-line treatment for high-risk NMIBC.
The approval of this facility also triggers a final $200 million payment from Royalty Pharma (RPRX, Financial) to Ferring Pharmaceuticals as part of their existing royalty-based financing agreement.
